Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Other Operating Expenses (2020 - 2024)

Longeveron (LGVN) posted quarterly Other Operating Expenses of -$100000.0 for Q3 2024, down 281.82% year-over-year from $55000.0 in Q4 2023, and little changed quarter-over-quarter from -$100000.0 in Q2 2024.

Longeveron (LGVN) Other Operating Expenses (2020 - 2024) Analysis & Trends

Longeveron's Other Operating Expenses history runs 5 years deep, the most recent figure standing at -$100000.0 for Q3 2024.

  • In Q3 2024, Other Operating Expenses fell 281.82% year-over-year to -$100000.0; the TTM figure through Jun 2025 stood at -$100000.0 (down 122.22% YoY), while the FY2025 annual figure was -$97000.0, changed N/A from the prior year.
  • Other Operating Expenses for Q3 2024 stood at -$100000.0, roughly flat from -$100000.0 in the prior quarter.
  • The five-year high for Other Operating Expenses was $7.0 million in Q4 2021, with the low at -$1.4 million in Q2 2022.
  • The 5-year median for Other Operating Expenses is $288000.0 (2020), against an average of $913437.5.
  • The sharpest annual moves came in 2021 and 2024: Other Operating Expenses jumped 250.09% in 2021, then tumbled 281.82% in 2024.
  • Longeveron's Other Operating Expenses stood at $2.5 million in 2020, then surged by 174.66% to $7.0 million in 2021, then sank by 95.91% to $285000.0 in 2022, then slumped by 80.7% to $55000.0 in 2023, then sank by 281.82% to -$100000.0 in 2024.
  • Business Quant data shows LGVN's Other Operating Expenses at -$100000.0 in Q3 2024, -$100000.0 in Q2 2024, and $55000.0 in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00

Historic Data

Download Data
DateValue
Sep 30, 2024 -100,000.00
Jun 30, 2024 -100,000.00
Sep 30, 2023 55,000.00
Jun 30, 2023 80,000.00
Dec 31, 2022 285,000.00
Sep 30, 2022 -57,000.00
Jun 30, 2022 -1.40 Mn
Mar 31, 2022 287,000.00
Dec 31, 2021 6.96 Mn
Sep 30, 2021 2.05 Mn
Jun 30, 2021 1.96 Mn
Mar 31, 2021 550,000.00
Dec 31, 2020 2.53 Mn
Sep 30, 2020 585,000.00
Jun 30, 2020 642,000.00
Mar 31, 2020 289,000.00